Published in Clin Pharmacol Ther on March 05, 2008
Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics. J Clin Invest (2012) 1.26
Pharmacotherapy in the treatment of addiction: methadone. J Addict Dis (2010) 1.23
Breaking barriers in the genomics and pharmacogenetics of drug addiction. Clin Pharmacol Ther (2010) 1.05
Drug-induced and genetic alterations in stress-responsive systems: Implications for specific addictive diseases. Brain Res (2009) 1.01
Bidirectional translational research: Progress in understanding addictive diseases. Neuropharmacology (2008) 0.99
Ethnicity interacts with the OPRM1 gene in experimental pain sensitivity. Pain (2012) 0.94
Mu-opioid receptor A118G polymorphism in healthy volunteers affects hypothalamic-pituitary-adrenal axis adrenocorticotropic hormone stress response to metyrapone. Addict Biol (2011) 0.88
Human behavioral pharmacology, past, present, and future: symposium presented at the 50th annual meeting of the Behavioral Pharmacology Society. Behav Pharmacol (2010) 0.87
Association of polymorphisms of the mu opioid receptor gene with the severity of HIV infection and response to HIV treatment. J Infect Dis (2012) 0.87
Overview and historical perspective of four papers presented on research related to the endogenous opioid system. Drug Alcohol Depend (2010) 0.82
Characterizing intercellular signaling peptides in drug addiction. Neuropharmacology (2008) 0.81
The role of functional postsynaptic NMDA receptors in the central nucleus of the amygdala in opioid dependence. Vitam Horm (2010) 0.81
Tolerance and sensitization to chronic escalating dose heroin following extended withdrawal in Fischer rats: possible role of mu-opioid receptors. Psychopharmacology (Berl) (2012) 0.81
Functions of arginine vasopressin and its receptors: importance of human molecular genetics studies in bidirectional translational research. Biol Psychiatry (2011) 0.80
Association of Variants of Arginine Vasopressin and Arginine Vasopressin Receptor 1A With Severe Acetaminophen Liver Injury. Cell Mol Gastroenterol Hepatol (2017) 0.77
Dysregulation of diurnal cortisol secretion affects abstinence induction during a lead-in period of a clinical trial for depressed cocaine-dependent patients. Am J Addict (2013) 0.75
Extreme marginalization: addiction and other mental health disorders, stigma, and imprisonment. Ann N Y Acad Sci (2011) 0.75
Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat Neurosci (2005) 4.83
Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A (1998) 4.67
Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am J Psychiatry (2007) 4.37
A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology (2003) 3.66
Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcomes. Arch Gen Psychiatry (2006) 3.55
Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend (1998) 2.94
Pharmacotherapy of addictions. Nat Rev Drug Discov (2002) 2.31
Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev (2005) 2.23
The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J Neurochem (2007) 1.78
Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology (2005) 1.66
The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology (2002) 1.66
Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden. Mol Psychiatry (2004) 1.56
Genes associated with addiction: alcoholism, opiate, and cocaine addiction. Neuromolecular Med (2004) 1.42
Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacology (2005) 1.34
Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). Am J Med Genet B Neuropsychiatr Genet (2003) 1.29
The mu-opioid receptor polymorphism A118G predicts cortisol responses to naloxone and stress. Neuropsychopharmacology (2006) 1.26
Redefinition of the human kappa opioid receptor gene (OPRK1) structure and association of haplotypes with opiate addiction. Pharmacogenetics (2004) 1.16
Opioid receptor and peptide gene polymorphisms: potential implications for addictions. Eur J Pharmacol (2000) 1.12
An allelic variation in the human prodynorphin gene promoter alters stimulus-induced expression. J Neurochem (2000) 1.10
Altered HPA axis responsivity to metyrapone testing in methadone maintained former heroin addicts with ongoing cocaine addiction. Neuropsychopharmacology (2001) 1.08
Stress responsivity, addiction, and a functional variant of the human mu-opioid receptor gene. Mol Interv (2007) 1.08
Prodynorphin gene promoter repeat associated with cocaine/alcohol codependence. Addict Biol (2007) 1.06
Suppressed prolactin response to dynorphin A1-13 in methadone-maintained versus control subjects. J Pharmacol Exp Ther (2003) 1.01
Altered levels of basal cortisol in healthy subjects with a 118G allele in exon 1 of the Mu opioid receptor gene. Neuropsychopharmacology (2006) 1.00
Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism. Alcohol Clin Exp Res (1998) 0.99
Confirmation of the association between a polymorphism in the promoter region of the prodynorphin gene and cocaine dependence. Am J Med Genet B Neuropsychiatr Genet (2005) 0.97
Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions. J Pharmacol Exp Ther (1999) 0.95
Corticotropin-releasing factor testing reveals a dose-dependent difference in methadone maintained vs control subjects. Neuropsychopharmacology (2003) 0.95
Glucocorticoid negative feedback in methadone-maintained former heroin addicts with ongoing cocaine dependence: dose-response to dexamethasone suppression. Addict Biol (2006) 0.92
Evolving perspectives on neurobiological research on the addictions: celebration of the 30th anniversary of NIDA. Neuropharmacology (2004) 0.88